Underwriting AgreementUnderwriting Agreement • January 18th, 2018 • AveXis, Inc. • Biological products, (no disgnostic substances) • New York
AveXis, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”) an aggregate of 3,921,600 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 588,240 additional shares (the “Optional Shares”) of Common Stock, par value $0.0001 (“Stock”) of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”.
